BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/10/2026 10:35:32 AM | Browse: 4 | Download: 46
 |
Received |
|
2025-03-31 04:18 |
|
Peer-Review Started |
|
2025-04-08 09:00 |
|
First Decision by Editorial Office Director |
|
2025-05-07 02:15 |
|
Return for Revision |
|
2025-05-07 02:15 |
|
Revised |
|
2025-05-20 02:27 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-08-04 02:52 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-08-04 10:08 |
|
Articles in Press |
|
2025-08-04 10:08 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-01-30 05:49 |
|
Publish the Manuscript Online |
|
2026-02-10 10:35 |
| ISSN |
2222-0682 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Mirtazapine for the treatment of irritable bowel syndrome: A systematic review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Raluca Prodan and Jonathan Soldera |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jonathan Soldera, PhD, Department of Gastroenterology, University of South Wales in Association with Learna Ltd., Cemetery Road, Cardiff CF37 1DL, United Kingdom. jonathansoldera@gmail.com |
| Key Words |
Irritable bowel syndrome; Mirtazapine; Antidepressants; Quality of Life; Rome criteria |
| Core Tip |
This study highlights the potential of mirtazapine in treating refractory irritable bowel syndrome (IBS), particularly diarrhea-predominant IBS with comorbid depression. By integrating a systematic review with a detailed case report, our findings demonstrate that mirtazapine, combined with Rifaximin, a low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol diet, and probiotics, significantly improves patient outcomes. This work emphasizes the importance of thorough diagnostic evaluation in IBS and supports further randomized controlled trials to confirm mirtazapine's efficacy. |
| Publish Date |
2026-02-10 10:35 |
| Citation |
Prodan R, Soldera J. Mirtazapine for the treatment of irritable bowel syndrome: A systematic review. World J Methodol 2026; 16(1): 107908 |
| URL |
https://www.wjgnet.com/2222-0682/full/v16/i1/107908.htm |
| DOI |
https://dx.doi.org/10.5662/wjm.v16.i1.107908 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
